Natco Pharma was represented by Anand Grover, on instructions from Rajeshwari H, managing partner of Rajewshwari & Associates, when Delhi High Court recently allowed Natco to export sorafenib tosylate, a drug patented by Bayer for which Natco had obtained a compulsory licence in 2012. Bayer Corporation was represented by senior advocate Sudhir Chandra, on instructions from advocate Arun Kumar Jana and Perfexio Legal managing partner Sanjay Kumar and partner Arpita Sawhney.
Natco will export the drug to China for experimental purposes – a move that the court said does not amount to patent infringement, as it is allowed under an exemption provided in section 107A of the Patents Act, 1970.
Speaking to India Business Law Journal Rajeshwari H, who was assisted by Aparna Gaur, Tahir AJ and Gajendra, lawyers at the firm, said the ruling was significant as it “clarifies the situation for India’s generics industry”.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
